Home › Head and Neck Squamous Cell Carcinoma › New York
Head and Neck Squamous Cell Carcinoma clinical trials in New York
54 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in New York.
Cities in New York
- New York City39 studies
- Queens20 studies
- Greenburgh9 studies
- Staten Island9 studies
- The Bronx9 studies
- New Rochelle7 studies
- Buffalo7 studies
- Syracuse3 studies
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Montefiore Medical Center, The Bronx
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Richmond University Medical Center, Staten Island
- Montefiore Medical Center, The Bronx
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT04892173A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
- Montefiore Medical Center, The Bronx
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT07219212BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05136196Intratumoral N17350 in Advanced Solid Tumors
- Roswell Park Comprehensive Cancer Center, Buffalo
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Mount Sinai Union Square, New York
- and 9 more
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Sep 22, 2026 · NCT04671667Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06589804Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- START New York, Lake Success
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07730021Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
- Perlmutter Cancer Center at NYU Langone Health, Mineola
- Perlmutter Cancer Center at NYU Langone Health, New York
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 15, 2026 · NCT05952934Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Northwell Health Imbert Cancer Center, Bay Shore
- Northwell Health/Center for Advanced Medicine, Lake Success
- Long Island Jewish Medical Center, New Hyde Park
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Research Site, New York
- Research Site, Stony Brook
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06535607First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Mount Sinai, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06657222A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Site 107 - START New York - Long Island, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07462377ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06597721A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06465069A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- Roswell Park Cancer Institute, Buffalo
- START New York Long Island, Lake Success
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07602842A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- Mount Sinai Hospital, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06163534A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, New York
- Research Site, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT05877599A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- University of Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06769698Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06995508Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- and 4 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
- Stony Brook University Medical Center, Stony Brook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07441681Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT05985655A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT05859074A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT05544136A Study of MGC026 in Participants With Advanced Solid Tumors
- START-New York Long Island, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
- Exelixis Clinical Site #76, Syracuse
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05176483A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
- Clinical Research Alliance, Inc, Westbury
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Cayuga Medical Center, Ithaca
- Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT03526835A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06150664The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
- Mount Sinai Health System, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05419089A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT04722523FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0155, New York
- Site#0142, New York
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 17, 2026 · NCT06788990First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, Babylon
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, Brooklyn
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New Hyde Park
- and 7 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- START New York Long Island, LLC, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT07503808Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04777994A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Recruiting
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05889091From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.